X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (16937) 16937
Newsletter (192) 192
Book / eBook (35) 35
Magazine Article (29) 29
Book Chapter (23) 23
Newspaper Article (18) 18
Reference (4) 4
Conference Proceeding (3) 3
Dissertation (3) 3
Transcript (3) 3
Web Resource (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (15166) 15166
science & technology (13067) 13067
life sciences & biomedicine (12667) 12667
female (7850) 7850
oncology (7507) 7507
male (6314) 6314
middle aged (5060) 5060
adult (4491) 4491
antineoplastic combined chemotherapy protocols - therapeutic use (4427) 4427
cancer (4306) 4306
antineoplastic agents - therapeutic use (4204) 4204
antineoplastic agents, alkylating - therapeutic use (4165) 4165
chemotherapy (4110) 4110
aged (4074) 4074
animals (3756) 3756
treatment outcome (3261) 3261
hematology (2449) 2449
care and treatment (2259) 2259
pharmacology & pharmacy (2125) 2125
dacarbazine - analogs & derivatives (2000) 2000
medicine & public health (1981) 1981
combined modality therapy (1951) 1951
antineoplastic agents (1932) 1932
antineoplastic agents - pharmacology (1847) 1847
antineoplastic agents, alkylating - administration & dosage (1783) 1783
prognosis (1726) 1726
mice (1713) 1713
neoplasms - drug therapy (1696) 1696
research (1683) 1683
antimitotic agents (1655) 1655
dacarbazine - therapeutic use (1646) 1646
brain neoplasms - drug therapy (1527) 1527
cell line, tumor (1484) 1484
health aspects (1439) 1439
antineoplastic agents - adverse effects (1418) 1418
antineoplastic combined chemotherapy protocols - adverse effects (1407) 1407
temozolomide (1388) 1388
adolescent (1382) 1382
aged, 80 and over (1345) 1345
retrospective studies (1329) 1329
disease-free survival (1303) 1303
drug therapy (1254) 1254
analysis (1249) 1249
antineoplastic agents - administration & dosage (1247) 1247
cyclophosphamide - administration & dosage (1222) 1222
tumors (1200) 1200
antineoplastic agents, alkylating - adverse effects (1197) 1197
child (1154) 1154
survival analysis (1146) 1146
dose-response relationship, drug (1074) 1074
survival rate (1071) 1071
abridged index medicus (1070) 1070
apoptosis (1064) 1064
follow-up studies (995) 995
neurosciences & neurology (984) 984
breast neoplasms - drug therapy (980) 980
cyclophosphamide - therapeutic use (975) 975
neoplasm staging (927) 927
glioblastoma - drug therapy (913) 913
hematology, oncology and palliative medicine (912) 912
clinical neurology (910) 910
cyclophosphamide (907) 907
clinical trials as topic (905) 905
radiotherapy (896) 896
antineoplastic agents, alkylating - pharmacology (893) 893
time factors (879) 879
multiple myeloma - drug therapy (866) 866
drug resistance, neoplasm (857) 857
risk factors (854) 854
breast cancer (842) 842
drug administration schedule (831) 831
apoptosis - drug effects (819) 819
cancer therapies (817) 817
antineoplastic combined chemotherapy protocols - administration & dosage (813) 813
young adult (797) 797
glioblastoma (793) 793
surgery (771) 771
multiple myeloma (748) 748
child, preschool (743) 743
brain neoplasms - pathology (709) 709
clinical trials (697) 697
glioma - drug therapy (688) 688
remission induction (671) 671
transplantation (670) 670
drug resistance (663) 663
glioblastoma multiforme (660) 660
disease progression (656) 656
pharmacology/toxicology (645) 645
drug therapy, combination (643) 643
doxorubicin - administration & dosage (641) 641
cancer research (632) 632
dosage and administration (632) 632
metastasis (630) 630
chemotherapy, adjuvant (627) 627
gliomas (607) 607
stem cells (606) 606
toxicity (594) 594
cell survival - drug effects (590) 590
biochemistry & molecular biology (588) 588
brain neoplasms - therapy (586) 586
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16696) 16696
French (175) 175
German (148) 148
Japanese (131) 131
Russian (91) 91
Spanish (54) 54
Italian (33) 33
Chinese (30) 30
Polish (19) 19
Hungarian (14) 14
Norwegian (13) 13
Czech (11) 11
Dutch (11) 11
Portuguese (8) 8
Serbian (4) 4
Swedish (4) 4
Bulgarian (3) 3
Hebrew (3) 3
Ukrainian (3) 3
Croatian (2) 2
Finnish (2) 2
Lithuanian (2) 2
Arabic (1) 1
Korean (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer chemotherapy and pharmacology, ISSN 0344-5704, 8/2011, Volume 68, Issue 2, pp. 445 - 455
The natural flavonoid fisetin was recently identified as a lead compound that stabilizes endothelial cell microtubules. In this study, we investigated the... 
Fisetin | Lewis lung carcinoma | Angiogenesis | Antitumour activity | Cyclophosphamide | Medicine & Public Health | Cancer Research | Oncology | Cytotoxicity | EA·hy 926 endothelial cells | Pharmacology/Toxicology | Flavonoid | EA•hy 926 endothelial cells | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | NIH 3T3 Cells | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Tubulin Modulators - pharmacology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - pharmacology | Flavonoids - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Flavonoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Flavonoids - administration & dosage | Tubulin Modulators - administration & dosage | Female | Flavonoids - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Angiogenesis Inhibitors - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Cell Line | Cell Survival - drug effects | Tubulin Modulators - adverse effects | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Tubulin Modulators - therapeutic use | Carcinoma, Lewis Lung - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Cell Movement - drug effects | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endothelial Cells - cytology | Neovascularization, Pathologic - drug therapy | Cyclophosphamide - pharmacology | Carcinoma, Lewis Lung - pathology | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Alkylating - adverse effects | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Endothelial Cells - drug effects | Antimitotic agents | Flavonoids | Flavones | Lung cancer | Bioflavonoids | Accountants | Drug therapy, Combination | Universities and colleges | Antineoplastic agents | Endothelium | Tumors | Index Medicus | cytology | Antineoplastic Agents, Phytogenic | pathology | Cell Proliferation | Endothelial Cells | Tubulin Modulators | Neovascularization, Pathologic | fisetin | administration & dosage | pharmacology | flavonoid | Carcinoma, Lewis Lung | Antineoplastic Agents, Alkylating | cytotoxicity | drug therapy | Cell Survival | angiogenesis | Antineoplastic Combined Chemotherapy Protocols | drug effects | Tumor Burden | Angiogenesis Inhibitors | EA.hy 926 | Cell Cycle | antitumour activity | adverse effects | therapeutic use | Cell Movement
Journal Article
Clinical cancer research, ISSN 1557-3265, 05/2008, Volume 14, Issue 10, pp. 2900 - 2908
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1215 - 1223
Journal Article
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 71, pp. 43 - 50
Journal Article